Curasight A/S
Carsten Haagen Nielsen is a Co-founder and CEO of Minerva Imaging, a position held since November 2011. Prior to this role, Carsten was a Ph.D. student at the University of Copenhagen from August 2011 to March 2016, following a tenure as a Visiting Researcher at Stanford University School of Medicine from June 2007 to December 2010. Carsten holds a Doctor of Philosophy in Medical and Molecular Imaging from the University of Copenhagen (2011-2016) and a Master of Science in Biomedical Engineering from both the Technical University of Denmark and the University of Copenhagen (2003-2009). Additionally, further business education was pursued at Harvard Business School from 2013 to 2014.
This person is not in any teams
Curasight A/S
Curasight is a biotech company focused on addressing the need for improved diagnosis and treatment of several cancer indications. The Company has developed a highly specific PET (Positron emission tomography) imaging ligand, uTRACE®, targeting the receptor uPAR, which is a biomarker only expressed in cancer. uTRACE® will become a game-changer inthe diagnosis and treatment of cancer patients.In addition, with the promising results obtained within diagnostics Curasight will also pursues uPAR targeted radionuclide therapy using the uTREAT® ligand. As PET imaging and radionuclide therapy is based on the same uPAR binding peptide, a uTRACE® scan can precisely predict where subsequent targeted radiation therapy will be delivered. uTRACE® covers the diagnostic path and uTREAT® covers the therapy. This will be the new management and treatment of cancer patients in the future.